000			01900nam a2200277 a 4500
001			vtls000043037
003			KUKTEM
005			20251117145148.0
008			090902t2009 enka b 001 0 eng
020			_a9780470092545 (hbk)
020			_a0470092548 (hbk)
020			_a9780470092552 (pbk)
020			_a0470092556 (pbk)
039		9	_a201107132032 _bVLOAD _c201008190925 _djamie _y200909021419 _zfarina
090			_aRC271.C5 A57 2009
100	1		_aAirley, Rachel.
245	1	0	_aCancer chemotherapy / _cRachel Airley
260			_aChichester, UK ; _aHoboken, NJ : _bWiley-Blackwell, _c2009
300			_ax, 341 p., [8] p. of plates : _bill. (some col.) ; _c25 cm.
504			_aIncludes bibliographical references and index
505	0		_aCancer epidemiology -- Histopathology of cancer -- Carcinogenesis, malignant transformation, and progression -- Molecular biology of cancer : oncogenes and tumour suppressor genes -- Tumour metastasis : a convergence of many theories -- Health professionals in the treatment of cancer -- Principles of cancer chemotherapy -- Classic anticancer agents -- The philosophy of cancer research -- Novel anticancer agents -- Clinical trials -- Tumour hypoxia -- Antiangiogenic and antivascular agents -- Tyrosine kinase inhibitors -- Ras inhibitors -- Inhibitors of the Akt/PKB pathway -- Targeting stress proteins: HSP90 inhibitors -- The proteasome -- Checkpoint protein kinases as novel targets : mammalian target of rapamycin (mTOR) -- Telomerase -- Histone deacetylase : an epigenetic drug target -- Pharmaceutical problems in cancer chemotherapy -- Oncology pharmacy at home and abroad -- Practice exam questions
650		0	_aCancer _xChemotherapy
650	1	2	_aNeoplasms _xdrug therapy
650	2	2	_aAntineoplastic Agents _xtherapeutic use
999			_aVIRTUA40 _c40629 _d40635
999			_aVTLSSORT0080*0200*0201*0202*0203*0900*1000*2450*2600*3000*5040*5050*6500*6501*6502*9991